Pay in 4 interest-free payments of $6.64 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Q2 2025 Snapshot Eli Lilly and Company dominates the US 57 % GLP-1 share, led by Mounjaro (tirzepatide) HCP & Zepbound (tirzepatide) HCP Novo Nordisk rules Europe 63 % value share, powered by Wegovy(semaglutide) injection 2.4 mg HCP & Ozempic APAC & Emerging Markets are the next frontier (+1113 % YoY) Together, they crossed $24 Billion in H1 2025 GLP-1 revenue proving the real blockbuster of this decade isnt oncology or immunology Its metabolic health
PubMed Systematic umbrella review evaluating nutritional supplements including niacinamide for primary prevention of skin diseases across 9,229 participants, examining preventive effects against ultraviolet radiation-induced skin pathology and other dermatological conditions
Patients should inform their healthcare provider about all ongoing treatments
Twenty-five serious side effects occurred in 18 participants (17.6%) in the placebo arm and seven participants (6.9%) in the treatment arm
A malnourished mother on any weight loss medication, GLP-1 or otherwise, poses significant risk
US$ 21.93
US$ 21.65
US$ 29.39
US$ 23.22
US$ 24.14
